Stockreport

Akero Therapeutics' efruxifermin meets primary endpoint in mid-stage NASH trial [Seeking Alpha]

Akero Therapeutics, Inc.  (AKRO) 
Last akero therapeutics, inc. earnings: 3/16 07:30 am Check Earnings Report
PDF Akero Therapeutics' efruxifermin meets primary endpoint in mid-stage NASH trial [Read more]